THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
发明人:
申请号：
ARP170101457
公开号：
AR108624A1
申请日:
2017.05.26
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Claim 1: a method of treating cancer in a subject.The Method comprises administering to the subject an inhibitor of immune Control Point and a composition comprising Cytotoxic T Cells (CTL) expressing a specific T cell receptorCO for a Peptide associated with Cancer presented in a MHC class I.Claim 2: the method of claim 1 wherein the Control Point immune inhibitor is a Protein or polypeptide that binds to a Protein of the immune Control Point.Claim 3: the method of claim 2, wherein the Control Point is immune Protein of CTLA4, pd-1, Pd Pd - L1, L2, a2ar, b7-h3 and b7-h4, BTLa, KIR, lag-3, Tim - 3, Gone, TDO or view.Claim 8: the method of claim 1, wherein the inhibitor of immune Control Point is nivolumab, pembrolizumab, pidilizumab 224, AMP, AMP - 514, STI - A1110, TSR 042, RG 7446,- 936559 BMS BMS - 936558, MK - 3475, cto11, mpdl3280a, Medi - 0020718c 4736, MSB, AUR - 012 - A1010 and STI.The Method of claim claim 10: 9, where the viral Peptide is a Peptide of Epstein Barr Virus (EBV).The Method of claim 14: any one of claims 1 to 13, where the Cancer is nasopharyngeal carcinoma (NPC).The Method of claim 18: any of the preceding Claims, wherein the CTL and the inhibitor of immune Control Point are given together.The Method of claim 19: any of the preceding Claims, wherein the CTL and the inhibitor of immune Control Point are given sequentially.Claim 21: a method of treatment or prevention of cancer in a subject.Comprising: (a) to incubate a sample comprising CTL and Antigen Presenting Cells (APC) with CMV peptide.Inducing the Proliferation of CTL specific Peptide in the sample.(b) manage the subject specific CTL peptides in combination with an inhibitor of immune Control Point.The Method of claim 34: claim 21 to 33, where the sample includes peripheral blood mononuclear Cells (PBMC).Reivindicación 1: Un método de tratamiento del cáncer en un sujeto, comprendiendo el método administrar al sujeto un inhibidor del punto de control inmunológico y una composición que co
